Phase Ib/II Trial of Sonrotoclax and BCMA Bispecific Antibody in Systemic AL Amyloidosis
A phase Ib/II trial is evaluating sonrotoclax plus dexamethasone in newly diagnosed systemic AL amyloidosis patients based on t(11;14) genetic stratification.
Therapeutic Area
Therapeutic area intelligence for Systemic AL Amyloidosis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.